nabilone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1862 51022-71-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nabilone
  • cesamet
  • LY 109514
  • LY-109514
cannabinol deriv; RN given refers to cpd without isomeric designation; structure
  • Molecular weight: 372.55
  • Formula: C24H36O3
  • CLOGP: 6.72
  • LIPINSKI: 1
  • HAC: 3
  • HDO: 1
  • TPSA: 46.53
  • ALOGS: -5.88
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
3 mg O

ADMET properties:

PropertyValueReference
BA (Bioavailability) 20 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Dec. 26, 1985 FDA MEDA PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
White blood cell count abnormal 289.11 25.80 67 2978 5065 46677952
Somatic symptom disorder 140.27 25.80 31 3014 1881 46681136
Sacroiliitis 136.38 25.80 31 3014 2138 46680879
Gait disturbance 134.69 25.80 95 2950 145168 46537849
Musculoskeletal stiffness 134.59 25.80 82 2963 97911 46585106
Rheumatoid arthritis 92.93 25.80 95 2950 240120 46442897
Insomnia 92.07 25.80 80 2965 164844 46518173
Mood altered 85.17 25.80 32 3013 12975 46670042
Therapeutic product effect incomplete 71.90 25.80 51 2994 78102 46604915
Drug hypersensitivity 67.47 25.80 81 2964 243744 46439273
Pain 66.31 25.80 114 2931 476834 46206183
Cognitive disorder 58.62 25.80 34 3011 36849 46646168
Therapeutic response shortened 57.89 25.80 19 3026 5180 46677837
Fibromyalgia 53.70 25.80 32 3013 36431 46646586
Occult blood 51.66 25.80 12 3033 908 46682109
Acute psychosis 42.46 25.80 12 3033 1980 46681037
Dystonia 34.08 25.80 16 3029 11241 46671776
Iron deficiency 30.27 25.80 12 3033 5601 46677416
Psychotic disorder 28.55 25.80 18 3027 22603 46660414

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pelvic pain 45.75 38.84 11 889 2118 29949460
Immune-mediated hepatitis 41.41 38.84 9 891 1107 29950471

Pharmacologic Action:

SourceCodeDescription
ATC A04AD11 ALIMENTARY TRACT AND METABOLISM
ANTIEMETICS AND ANTINAUSEANTS
ANTIEMETICS AND ANTINAUSEANTS
Other antiemetics
FDA CS M0003267 Cannabinoids
FDA EPC N0000175782 Cannabinoid
MeSH PA D014151 Anti-Anxiety Agents
MeSH PA D000932 Antiemetics
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Chemotherapy-induced nausea and vomiting indication 236084000
Depressive disorder contraindication 35489007
Hypertensive disorder contraindication 38341003 DOID:10763
Conduction disorder of the heart contraindication 44808001
Low blood pressure contraindication 45007003
Chronic heart failure contraindication 48447003
Schizophrenia contraindication 58214004 DOID:5419
Hepatic failure contraindication 59927004
Substance abuse contraindication 66214007
Psychotic disorder contraindication 69322001
Mania contraindication 231494001
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.7 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Cannabinoid receptor 1 GPCR AGONIST Ki 8.40 CHEMBL CHEMBL
Cannabinoid receptor 2 GPCR Ki 8.20 CHEMBL
Cannabinoid receptor 1 GPCR Ki 8.66 CHEMBL
Cannabinoid receptor 2 GPCR Ki 8.74 CHEMBL

External reference:

IDSource
4019352 VUID
N0000147524 NUI
D05099 KEGG_DRUG
4019352 VANDF
C1263104 UMLSCUI
CHEBI:135574 CHEBI
CHEMBL2218896 ChEMBL_ID
CHEMBL947 ChEMBL_ID
DB00486 DRUGBANK_ID
C011941 MESH_SUPPLEMENTAL_RECORD_UI
5284592 PUBCHEM_CID
9071 IUPHAR_LIGAND_ID
3930 INN_ID
2N4O9L084N UNII
31447 RXNORM
15778 MMSL
38357 MMSL
52672 MMSL
d04587 MMSL
001686 NDDF
322124005 SNOMEDCT_US
395806009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cesamet HUMAN PRESCRIPTION DRUG LABEL 1 0187-1231 CAPSULE 1 mg ORAL NDA 22 sections